{"knowledge_schema": {"broad_category": "Oncology \u2192 Breast Cancer \u2192 HER2 Positive Metastatic Breast Cancer", "refinement": "This problem focuses on treatment options for patients with HER2 positive metastatic breast cancer (MBC) who have experienced disease progression after initial treatment with trastuzumab and a taxane.", "specific_scope": "The context is specifically about identifying a treatment option that has a category 1 recommendation from the National Comprehensive Cancer Network (NCCN) for this patient population.", "goal": "Determine which treatment option is recommended by the NCCN for patients with HER2+ MBC whose disease has progressed after prior therapies."}, "summary": "This problem involves understanding treatment guidelines for HER2 positive metastatic breast cancer, particularly in cases where the disease has progressed after initial therapies. The goal is to identify a treatment option that has a category 1 recommendation from the NCCN for patients in this situation. The options include various combinations of targeted therapies and chemotherapy, and the correct answer will reflect the most current and effective treatment strategy as per NCCN guidelines."}